VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey.

dc.authorid101949en_US
dc.contributor.authorMalkoçoğlu, Gülşah
dc.contributor.authorAktaş, Elif
dc.contributor.authorBayraktar, Banu
dc.contributor.authorOtlu, Barış
dc.contributor.authorBulut, Mehmet Emin
dc.date.accessioned2017-07-09T12:17:22Z
dc.date.available2017-07-09T12:17:22Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWorldwide increase in carbapenem resistance and transferable carbapenemases are significant challenges in treatment of Pseudomonas aeruginosa infections. In this study, investigation of carbapenemase production in carbapenem-resistant P. aeruginosa isolates recovered from clinical specimens in a tertiary hospital was aimed. A total of 84 carbapenem-resistant P. aeruginosa isolates were examined. "Carbapenem inactivation method" (CIM) was used for phenotypic detection of carbapenemase production. The existence of blaKPC, blaNDM, blaIMP, blaVIM, blaOXA-48, and blaGES genes was investigated by polymerase chain reaction (PCR). Subtypes of the detected genes were identified by sequence analysis. Arbitrarily primed PCR (AP-PCR) was performed to evaluate the clonal relationship among the isolates. The presence of high-risk clones in carbapenemase producers was investigated by Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Three isolates (3.5%) were identified as carbapenemase producers by CIM tests, while PCR tests demonstrated three isolates carrying carbapenemase genes as well. blaVIM gene was found in two isolates and blaGES gene was found in one isolate. Sequence analysis demonstrated that the carbapenemases were VIM-1, VIM-2, and GES-5. AP-PCR yielded high clonal diversity among the isolates. According to MALDI-TOF MS analysis, none of the carbapenemase-producing strains belonged to the high-risk clones. In conclusion, the presence of VIM-1, VIM-2, and GES-5 type carbapenemases in P. aeruginosa isolates was demonstrated for the first time in our hospital, GES-5 being reported for the second time in Turkey. Our results will lead strategies for controlling the spread of carbapenemases and contribute to epidemiological data from Turkey.en_US
dc.identifier.citationMalkoçoğlu, G. Aktaş, E. Bayraktar, B. Otlu, B. Bulut, M. E. (2017). VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey. Microbial Drug Resistance, 23(3), 328–334.en_US
dc.identifier.doi10.1089/mdr.2016.0012en_US
dc.identifier.endpage334en_US
dc.identifier.issue3en_US
dc.identifier.startpage328en_US
dc.identifier.urihttps://hdl.handle.net/11616/7342
dc.identifier.volume23en_US
dc.language.isoenen_US
dc.publisherMicrobial Drug Resistanceen_US
dc.relation.ispartofMicrobial Drug Resistanceen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectGES-5en_US
dc.subjectPseudomonas aeruginosaen_US
dc.subjectTurkeyen_US
dc.subjectVIM-1en_US
dc.subjectVIM-2en_US
dc.subjectCarbapenemaseen_US
dc.titleVIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey.en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Makale Dosyası.docx
Boyut:
15.34 KB
Biçim:
Microsoft Word XML
Açıklama:
Makale Dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: